Stay On-Target With Novel, High-Fidelity Cas9
Complete the form below to unlock access to ALL audio articles.
Integrated DNA Technologies (IDT) will host a webinar titled "Increase on-target specificity of CRISPR genome editing using a novel, high-fidelity Cas9 nuclease” on August 16, 2017. The webinar will be presented by Dr Chris Vakulskas, Staff Scientist, Molecular Genetics at IDT. Dr Vakulskas will present data from the development of the novel Alt-R® S.p. HiFi Cas9 Nuclease 3NLS, as well as describe its benefits for improved specificity without compromising on-target activity.
Despite its revolutionary impact on life science research, the CRISPR/Cas9 genome editing system suffers from concerns related to target specificity, particularly for researchers considering therapeutic applications. Until now, modifications to guide RNAs and Cas9 proteins have been used to reduce off-target effects, but many of these have also reduced on-target editing. In this webinar, Dr Vakulskas will describe how his team developed the novel Alt-R S.p. HiFi Cas9 Nuclease 3NLS through an intensive screening and selection process. Webinar attendees will learn about the benefits and usefulness of this this novel nuclease as part of a ribonucleoprotein (RNP) complex to mitigate unwanted off-target gene editing.
